ClinicalTrials.gov
ClinicalTrials.gov Menu

Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01678976
Recruitment Status : Completed
First Posted : September 5, 2012
Results First Posted : January 8, 2015
Last Update Posted : January 8, 2015
Sponsor:
Information provided by (Responsible Party):
Bial - Portela C S.A.

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Epilepsy
Interventions: Drug: BIA 2-093
Drug: Oxcarbazepine

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Period 1 - BIA 2-093; Period 2 - Oxcarbazepine Period 1 - Subjects recieved 900 mg of BIA 2-093 Period 2 - Subjects recieved 900 mg of oxcarbazepine
Period 1 - Oxcarbazepine; Period 2 - BIA 2-093 Period 1 - Subjects recieved 900 mg of oxcarbazepine Period 2 - Subjects recieved 900 mg of BIA 2-093

Participant Flow for 2 periods

Period 1:   First Period
    Period 1 - BIA 2-093; Period 2 - Oxcarbazepine   Period 1 - Oxcarbazepine; Period 2 - BIA 2-093
STARTED   6   7 
COMPLETED   6   6 
NOT COMPLETED   0   1 

Period 2:   Second Period
    Period 1 - BIA 2-093; Period 2 - Oxcarbazepine   Period 1 - Oxcarbazepine; Period 2 - BIA 2-093
STARTED   6   6 
COMPLETED   6   6 
NOT COMPLETED   0   0 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Period 1 - BIA 2-093; Period 2 - Oxcarbazepine Period 1 - Subjects recieved 900 mg of BIA 2-093 Period 2 - Subjects recieved 900 mg of oxcarbazepine
Period 1 - Oxcarbazepine; Period 2 - BIA 2-093 Period 1 - Subjects recieved 900 mg of oxcarbazepine Period 2 - Subjects recieved 900 mg of BIA 2-093
Total Total of all reporting groups

Baseline Measures
   Period 1 - BIA 2-093; Period 2 - Oxcarbazepine   Period 1 - Oxcarbazepine; Period 2 - BIA 2-093   Total 
Overall Participants Analyzed 
[Units: Participants]
 6   6   12 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   6   6   12 
>=65 years   0   0   0 
Gender 
[Units: Participants]
     
Female   3   3   6 
Male   3   3   6 


  Outcome Measures

1.  Primary:   Maximum Drug Concentration (Cmax)   [ Time Frame: at pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72 and 96 hours post-dose ]

2.  Secondary:   Area Under the Plasma Concentration Versus Time Curve (AUC)   [ Time Frame: at pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72 and 96 hours post-dose ]

3.  Other Pre-specified:   Total of Subjects Reporting at Least One Adverse Event   [ Time Frame: 4 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Head of Clinical Research
Organization: Bial – Portela & Cª, S.A.
phone: +351 229 866 100
e-mail: francisco.rocha@bial.com



Responsible Party: Bial - Portela C S.A.
ClinicalTrials.gov Identifier: NCT01678976     History of Changes
Other Study ID Numbers: BIA-2093-104
First Submitted: August 31, 2012
First Posted: September 5, 2012
Results First Submitted: November 28, 2014
Results First Posted: January 8, 2015
Last Update Posted: January 8, 2015